
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.

Professor of rheumatology at the University of Pisa and head of the Rheumatology Unit at the Azienda Ospedaliero Universitaria Pisana, Italy. She is also head of the Fellowship Training Program in Rheumatology at the University of Pisa and a faculty member of the Ph.D. program in Genetics, Oncology and Clinical Medicine of the Consortium comprising the Universities of Pisa, Florence, and Siena